Cancer trial enrollment after state-mandated reimbursement

Area of Science:

• Oncology
• Health Services Research
• Health Policy

Background:

• Patient recruitment for cancer research, especially early-phase trials, faces significant challenges.
• Payer reimbursement policies are identified as a major barrier to clinical trial participation.
• This study investigates the impact of state policies mandating coverage for routine care costs on cancer trial enrollment.

Purpose of the Study:

• To determine if state policies ensuring coverage of routine medical care costs for cancer trial participants are associated with increased clinical trial enrollment.
• To analyze the differential impact of such policies on phase II versus phase III cancer trials.

Main Methods:

• Utilized logistic Poisson regressions to analyze enrollment data for National Cancer Institute (NCI) phase II and III Clinical Trials Cooperative Group trials.
• Compared changes in trial enrollment rates between 1996 and 2001 for privately insured cancer patients in states with and without coverage policies enacted in 1999.
• Employed two-sided statistical tests for all analyses.

Main Results:

• Overall trial enrollment increased annually in both coverage and non-coverage states from 1996-2001.
• Following policy implementation in 1999, phase II trial enrollment saw a significant annual increase (21.7%) in coverage states, contrasting with a decrease in non-coverage states.
• Multivariable analysis confirmed a 59% increased annual odds of phase II trial participation in coverage states post-1999 (OR=1.59).
• Phase III trial participation showed a slight decrease in odds within coverage states after 1999 (OR=0.90).

Conclusions:

• State coverage policies demonstrated a statistically significant positive association with increased participation in phase II cancer clinical trials.
• The implemented state coverage policies did not yield a significant increase in phase III cancer trial enrollment.
• Findings suggest that coverage mandates may effectively boost enrollment in earlier-phase cancer research.